Vascular Disease Foundation Inaugurates National Advisory Board with Diomed Holdings as Founding Member
Developer and marketer of Endovenous Laser Treatment (EVLT(R)) for varicose veins makes financial commitment as first member of national nonprofit's corporate advisory board.
Lakewood, CO (PRWEB) July 16, 2004
The Vascular Disease Foundation (VDF) announced today that Diomed Holdings, Inc., (Amex: DIO), developer and marketer of the proprietary Endovenous Laser Treatment (EVLT(R)) for varicose veins, is the inaugural member of the Foundation's new National Advisory Board and will sponsor a portion of the Foundation's website dedicated to venous disease. Diomed's President and Chief Executive Officer, James A. Wylie, Jr., will serve on behalf of the company on the Foundation's Advisory Board.
"We are delighted to announce that Diomed has made a significant commitment to the Vascular Disease Foundation's future," said Peter Gloviczki, M. D., President of VDF's board of directors. "The goal of the Vascular Disease Foundation's new National Advisory Board is to reduce the mortality and morbidity from vascular diseases. The Advisory Board is allied with the Foundation in the belief that patient quality of life and longevity can be improved through education and prevention, prompt diagnosis, comprehensive treatment and effective rehabilitation of arterial and venous disease. The VDF website offers guidance to thousands of visitors each month with educational support from companies such as Diomed."
Founded in 1998, VDF is one of the country's leading nonprofit patient information and education resources on the diagnosis and management of vascular diseases.
Commenting on the Advisory Board and web site sponsorship, James A Wylie, Diomed President and Chief Executive Officer, said, "It is really an honor to be working with the VDF in their endeavor to provide useful, timely and accurate information to thousands of patients. The VDF's mandate to inform patients about the array of vascular diseases is perfectly in line with Diomed's mandate to provide the latest in chronic venous disease treatment alternatives."
Wylie said it is estimated that more than 25 million Americans are affected by varicose veins or more severe forms of chronic venous disease and that Diomed is committed to provide solutions to this issue.
"Our membership in the VDF National Advisory Board and our VDF website sponsorship is part of a broader Diomed initiative to help advance patient education while supporting worthy causes surrounding vascular disease," Wylie stated.
About the Vascular Disease Foundation:
The Vascular Disease Foundation is a nonprofit educational organization dedicated to increasing the awareness of the prevention, diagnosis and management of vascular disease. Its board of directors includes renowned physicians and researchers from many specialties who have been active in fighting vascular diseases for many years.
For more information on the Vascular Disease Foundation, or on vascular diseases, call 1-866-723-4636 or visit www. vdf. org
About Diomed
Diomed develops and commercializes minimally invasive medical procedures that use its proprietary laser technologies and disposable products. Diomed focuses on EndoVenous Laser Treatment (EVLT(R)) for use in varicose vein treatments, photodynamic therapy (PDT) for use in cancer treatments, and dental and general surgical applications. The EVLT(R) procedure and the Company's related products were cleared by the United States FDA in January of 2002. Along with lasers and single-use procedure kits for EVLT(R), the Company provides its customers with state of the art physician training and practice development support. Additional information is available on the Company's website: www. diomedinc. com or www. evlt. com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995:
Statements in this news release looking forward in time involve risks and uncertainties. These statements relate to Diomed's future plans, objectives, expectations and intentions. These statements may be identified by the use of words such as "may," "will," "should," "potential," "expects," "anticipates," "intends," "plans," "believes" and similar expressions. These statements are based on Diomed's current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties. Diomed's actual results could differ materially from those discussed in these statements. Diomed's Annual Report on Form SEC 10-KSB/A (the "Annual Report") contains a discussion of certain of the risks and uncertainties that affect the business. You are referred to the "Risk Factors" of the Annual Report for a discussion of certain risks, including those relating to Diomed's business as a medical device company without a significant operating record and with operating losses, risks relating to Diomed's commercialization of its current and future products and applications and risks relating to its common stock and its market value. Diomed disclaims any obligation or duty to update or correct any of its forward-looking statements.
EVLT(R) is a registered trademark of Diomed Inc., Andover, MA
